Sotrovimab in Hospitalized Patients with SARS-CoV-2 Omicron Variant Infection: a Propensity Score-Matched Retrospective Cohort Study-Reference-Cited by-同舟云学术

Sotrovimab in Hospitalized Patients with SARS-CoV-2 Omicron Variant Infection: a Propensity Score-Matched Retrospective Cohort Study

Published:2023-02-14 Issue:1 Volume:11 Page:
ISSN:2165-0497
Container-title:Microbiology Spectrum
language:en
Short-container-title:Microbiol Spectr

Author:

Woo Marcel S.¹²,Brehm Thomas Theo³⁴^ORCID,Fischer Marlene⁵,Heyer Andreas³,Wichmann Dominic⁵,Jordan Sabine³,Nörz Dominik⁶^ORCID,Lütgehetmann Marc⁴⁶,Addo Marylyn M.³⁴⁷,Lohse Ansgar W.³⁴,Schmiedel Stefan³⁴,Kluge Stefan⁵,Schulze zur Wiesch Julian³⁴

Affiliation:

1. Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

2. Institute of Neuroimmunology and Multiple Sclerosis (INIMS), Center for Molecular Neurobiology Hamburg (ZMNH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany

3. I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

4. German Center for Infection Research (DZIF), University Medical Center Hamburg-Eppendorf, Lübeck-Borstel-Riems, Hamburg, Germany

5. Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

6. Institute of Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

7. Institute of Infection Research and Vaccine Development (IIRVD), University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Abstract

This study shows that among hospitalized patients with SARS-CoV-2 Omicron variant infection at risk of disease progression, treatment with sotrovimab alone or in combination with remdesivir did not decrease in-hospital mortality. These real-world clinical findings in combination with previous in vitro data about lacking neutralizing activity of sotrovimab against SARS-CoV-2 Omicron variant do not support sotrovimab as a treatment option in these patients.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology

Link

https://journals.asm.org/doi/pdf/10.1128/spectrum.04103-22

Reference18 articles.

1. WHO. 2022. WHO coronavirus (COVID-19) dashboard. https://covid19.who.int.

2. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

3. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

4. Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants

5. Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative analysis of characteristics and outcomes in hospitalized COVID-19 patients infected with different SARS-CoV-2 variants between January 2020 and April 2022 – A retrospective single-center cohort study;Journal of Infection and Public Health;2023-11

2. Monoclonal antibodies as COVID-19 prophylaxis therapy in immunocompromised patient populations;International Journal of Infectious Diseases;2023-09

3. What Is the Efficacy of Sotrovimab in Reducing Disease Progression and Death in People with COVID-19 during the Omicron Era? Answers from a Real-Life Study;Viruses;2023-08-17

4. Therapie von COVID-19 unter Berücksichtigung von Lebererkrankungen;Die Gastroenterologie;2023-03

5. Allogeneic hematopoietic stem cell transplantation in the COVID-19 era;Frontiers in Immunology;2023-02-22